Only three biomarker-drug-tumour combinations had both types of responses: the triplets ‘BRAF V600E-panitumumab, trametinib-colorectal cancer’, ‘EGFR R451C-cetuximab-colorectal cancer’ and ‘KRAS G13D-cetuximab-colorectal cancer’. Here, KRAS is linked to neoplasm.